Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on November 2, 2016. The report details a corporate governance action taken by the Board of Directors effective on the date of the report.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a bylaw amendment and does not contain financial statement data.
Material Changes
The material change reported is an amendment to the Company's Bylaws adopted by the Board of Directors. The amendment re-designates Section 58 as Section 59 and adds a new Section 58 establishing a forum selection provision. Unless the Company consents in writing to an alternative forum, the Court of Chancery of the State of Delaware is designated as the sole and exclusive forum for:
- Derivative actions brought on behalf of the Company.
- Actions asserting claims of breach of fiduciary duty by directors, officers, or employees.
- Actions arising under the Delaware General Corporation Law, the Certificate of Incorporation, or Bylaws.
- Actions governed by the internal affairs doctrine.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, or specific risk factors beyond the legal implications of the forum selection clause. The amendment is intended to centralize specific legal proceedings in Delaware.
Key Facts for Investor Verification
- Verify the effective date of the Bylaw amendment (November 2, 2016).
- Confirm the scope of the exclusive forum provision (Court of Chancery of Delaware).
- Review the full text of the amended Bylaws filed as Exhibit 3.1 for complete legal language.
- Note that this filing contains no financial performance data.